Brii Biosciences Limited (02137)
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody
Office
CS Hotline: +852 3018 4526
Trading days: 24 hours
Non-trading days: 9:00-18:00
Email: cs@usmarthk.com
Address: 26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp: +852 5989 2641
Physical Store
